您的位置: 首页 > 2023年8月 第54卷 第8期 > 文字全文
2023年7月 第38卷 第7期11
目录

血清H-FABP、Ang-1在急性大血管闭塞性卒中静脉溶栓桥接支架取栓患者预后评估价值

Prognostic value of serum H-FABP and Ang-1 in patients with ALS-LVO undergoing venous thrombolytic bridging stent thrombectomy

来源期刊: 广州医药 | 40-45 发布时间:2023-09-13 收稿时间:2025/11/13 18:31:44 阅读量:26
作者:
关键词:
急性大血管闭塞性卒中心型脂肪酸结合蛋白血管生成素-1预后评估静脉溶栓桥接支架取栓
acute ischemic stroke-large vessel occlusionheart type fatty acid binding proteinangiopoietin-1prognostic evaluationvenous thrombolysisbridging stent thrombectomy
DOI:
10.3969/j.issn.1000-8535.2023.08.007
收稿时间:
2023-01-06 
修订日期:
 
接收日期:
 
引用总数:
0  
目的 探讨血清心型脂肪酸结合蛋白(H-FABP)、血管生成素-1(Ang-1)在急性大血管闭塞性卒中(AIS-LVO)静脉溶栓桥接支架取栓患者预后中的评估价值。方法 选择2019年1月—2021年5月80例AIS-LVO患者作为研究对象,均接受静脉溶栓桥接支架取栓治疗,检测术前血清H-FABP、Ang-1水平,术后随访90 d将患者分为预后良好组(n=57)与预后不良组(n=23)。结果 两组在高血压、冠心病、心房颤动、急性卒中治疗低分子肝素试验(TOAST)分型、侧支循环、术前H-FABP、术前Ang-1方面存在差异(P<0.05)。多因素 Logistic 回归分析结果显示,高血压、心房颤动、心源性梗死型、侧支循环为0 ~1 级、术前H-FABP≥10.0 ng/L、术前Ang-1<5.25 ng/mL是AIS-LVO静脉溶栓桥接支架取栓患者预后不良的危险因素。术前血清H-FABP预测术后90 d预后不良的AUC为0.728(95%CI:0.368~0.918),灵敏度、特异度分别为66.68%、58.92%。术前血清Ang-1预测术后90 d预后不良的AUC为0.773(95%CI:0.592~1.129),灵敏度、特异度分别为70.35%、63.92%。H-FABP联合Ang-1预测术后90 d预后不良的AUC为0.854(95%CI:0.652~0.957),灵敏度、特异度分别为77.18%、71.82%。结论 静脉溶栓桥接支架取栓治疗AIS-LVO患者的预后受到多种危险因素的影响,其中术前血清H-FABP和Ang-1是具有前景的预后预测因子。
Objective To investigate the prognostic value of serum heart-type fatty acid binding protein(H-FABP)and angiopoietin-1(Ang-1)in patients with acute ischemic stroke-large vessel occlusion(ALS-LVO)undergoing venous thrombolytic bridging stent thrombectomy.Methods A total of 80 patients with ALS-LVO from January 2019 to May 2021 were selected as the study subjects,treated with intravenous thrombolytic bridging stent thrombectomy,and their serum H-FABP and Ang-1 levels were measured before operation.After 90 days of follow-up,the patients were divided into good prognosis group(n=57)and poor prognosis group(n=23).Results There were significant differences between the two groups in hypertension,coronary heart disease,atrial fibrillation,TOAST classification,collateral circulation,preoperative H-FABP,and preoperative Ang-1(P<0.05).Multivariate logistic regression analysis showed that hypertension,atrial fibrillation,cardiogenic infarction type,collateral circulation of 0~1 grade,preoperative H-FABP≥10.0 ng/L,preoperative Ang-1<5.25 ng/mL were independent risk factors for poor prognosis of ALS-LVO patients treated with venous thrombolytic bridging stents.The AUC of preoperative serum H-FABP predicting poor prognosis 90 days after operation was 0.728(95%CI:0.368~0.918),with sensitivity and specificity of 66.68% and 58.92% respectively.The AUC of preoperative serum Ang-1 predicting poor prognosis 90 days after surgery was 0.773(95%CI:0.592~1.129),with sensitivity and specificity of 70.35% and 63.92% respectively.The AUC predicted by H-FABP combined with Ang-1 for poor prognosis 90 days after operation was 0.854(95%CI:0.652~0.957),and the sensitivity and specificity were 77.18% and 71.82% respectively.Conclusions The prognosis of patients with ALS-LVO treated with intravenous thrombectomy bridging stent thrombectomy is affected by many risk factors,among which preoperative serum H-FABP and Ang-1 are promising prognostic factors.
1、 傅阳俊,方丽萍,彭俊,等.血管生成素1与急性缺血性卒中患者侧支循环的关系[J].中国脑血管病杂志,2018,15(8):408-413. 傅阳俊,方丽萍,彭俊,等.血管生成素1与急性缺血性卒中患者侧支循环的关系[J].中国脑血管病杂志,2018,15(8):408-413.
2、 方丽萍,傅阳俊,彭俊,等.血管生成素-1与急性缺血性脑卒中患者预后的关系[J].中华神经医学杂志,2018,17(10):1041-1044. 方丽萍,傅阳俊,彭俊,等.血管生成素-1与急性缺血性脑卒中患者预后的关系[J].中华神经医学杂志,2018,17(10):1041-1044.
3、 陈秀英,左旭政,程畅,等.血清SDF-1,Ang-1与急性缺血性脑卒中预后的关系及其预测价值[J].卒中与神经疾病,2020,27(2):166-170,184. 陈秀英,左旭政,程畅,等.血清SDF-1,Ang-1与急性缺血性脑卒中预后的关系及其预测价值[J].卒中与神经疾病,2020,27(2):166-170,184.
4、 王延,钱海兵.Ang-1/Tie-2信号通路与缺血性脑卒中的相关性研究述评[J].中国中医基础医学杂志,2021,27(1):170-172,177. 王延,钱海兵.Ang-1/Tie-2信号通路与缺血性脑卒中的相关性研究述评[J].中国中医基础医学杂志,2021,27(1):170-172,177.
5、 陈芳,杨红燕,李学英.脑梗死患者合并无症状心肌缺血的临床分析[J].中国医药指南,2014,12( 36):183-184. 陈芳,杨红燕,李学英.脑梗死患者合并无症状心肌缺血的临床分析[J].中国医药指南,2014,12( 36):183-184.
6、 AN S A,KIM J,KIM O J,et al.Limited clinical value of multiple blood markers in the diagnosis of ischemic stroke[J].Clin Biochem,2013,46(9):710-715. AN S A,KIM J,KIM O J,et al.Limited clinical value of multiple blood markers in the diagnosis of ischemic stroke[J].Clin Biochem,2013,46(9):710-715.
7、 张旭,南京柱.血清hFABP,hs-CRP及Hcy水平在脑梗死患者中的诊断价值[J].北华大学学报(自然科学版),2022,23(2):225-229. 张旭,南京柱.血清hFABP,hs-CRP及Hcy水平在脑梗死患者中的诊断价值[J].北华大学学报(自然科学版),2022,23(2):225-229.
8、 吴芳,刘悦,蔡志友.急性脑梗死患者神经功能缺损程度与血清H-FABP、CD62P水平的关系[J].卒中与神经疾病,2018,25(2):142-145,149. 吴芳,刘悦,蔡志友.急性脑梗死患者神经功能缺损程度与血清H-FABP、CD62P水平的关系[J].卒中与神经疾病,2018,25(2):142-145,149.
9、 WUNDERLICH M T,HANHOFF T,GRTLER M,et al.Release of brain-type and heart-type fatty acid-binding proteins in serum after acute ischaemic stroke[J].J Neurol,2005,252(6):718-724. WUNDERLICH M T,HANHOFF T,GRTLER M,et al.Release of brain-type and heart-type fatty acid-binding proteins in serum after acute ischaemic stroke[J].J Neurol,2005,252(6):718-724.
10、 陶鹏辉.Hs-CRP,CTnⅠ,H-FABP及VEGF-B对急性心肌梗死早期诊断的临床价值[J].实验与检验医学,2017,35(4):585-588. 陶鹏辉.Hs-CRP,CTnⅠ,H-FABP及VEGF-B对急性心肌梗死早期诊断的临床价值[J].实验与检验医学,2017,35(4):585-588.
11、 闫薪如,冯娟.血清血管生成素1水平与急性脑梗死发病、病情严重程度及90d 预后的关系[J].临床神经病学杂志,2016,29(2):113-116. 闫薪如,冯娟.血清血管生成素1水平与急性脑梗死发病、病情严重程度及90d 预后的关系[J].临床神经病学杂志,2016,29(2):113-116.
12、 刘相应,唐良秋,范文茂,等.直接经皮冠状动脉介入治疗术前、术后血清心型脂肪酸结合蛋白水平与急性ST段抬高心肌梗死患者预后的相关性[J].中国介入心脏病学杂志,2016,24(8):433-438. 刘相应,唐良秋,范文茂,等.直接经皮冠状动脉介入治疗术前、术后血清心型脂肪酸结合蛋白水平与急性ST段抬高心肌梗死患者预后的相关性[J].中国介入心脏病学杂志,2016,24(8):433-438.
13、 国家卫生健康委脑卒中防治工程委员会,中华医学会神经外科学分会神经介入学组,中华医学会放射学分会介入学组,等.急性大血管闭塞性缺血性卒中血管内治疗中国专家共识(2019年修订版)[J].中华神经外科杂志,2019,35(9):868-879. 国家卫生健康委脑卒中防治工程委员会,中华医学会神经外科学分会神经介入学组,中华医学会放射学分会介入学组,等.急性大血管闭塞性缺血性卒中血管内治疗中国专家共识(2019年修订版)[J].中华神经外科杂志,2019,35(9):868-879.
14、 MENON B K,AL-AJLAN F S,NAJM M,et al.Association of clinical,imaging,and thrombus characteristics with recanalization of visible intracranial occlusion in patients with acute ischemic stroke[J].JAMA,2018,320(10):1017-1026. MENON B K,AL-AJLAN F S,NAJM M,et al.Association of clinical,imaging,and thrombus characteristics with recanalization of visible intracranial occlusion in patients with acute ischemic stroke[J].JAMA,2018,320(10):1017-1026.
上一篇
下一篇
出版者信息








《广州医药》公众号
目录